
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is positioned for significant growth driven by key momentum factors, including anticipated Medicare expansion and additional coverage wins that are expected to increase the number of covered lives significantly. The company's focus on innovation, particularly with the G7 15-day continuous glucose monitoring system and improvements in adhesive technology enhancing sensor survival, supports a favorable outlook for revenue growth in the mid-teens and over 20% in earnings per share through 2028. Furthermore, operational efficiency gains and an expanding sales force are expected to contribute to sustained profitability, bolstering DexCom's overall financial performance.
Bears say
The financial analysis reveals a negative outlook on DexCom's stock due to several key factors: first, while sensor revenue has increased to $1.18 billion, the significant decline of 31% in hardware revenue signals potential weaknesses in product demand and diversification. Additionally, the company's forecast for Q1 2026 indicates a sequential revenue decline of 6-7%, suggesting ongoing challenges in maintaining consistent growth, especially as the sales mix shifts toward pharmacy distribution. Lastly, the fiscal year 2026 revenue guidance falls short of consensus expectations and indicates further deceleration in sales, which may lead to downward revisions in estimates, placing additional pressure on the stock.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares